Ding et al. (2021) also developed a ‘‘Sweet Tooth”-oriented SN38 prodrug delivery nanoplatform (Glu-SNP) for gastric cancer treatment based on the specific targeting of cancer cells exhibiting GLUT1 expression. This evidence concerns the gene SLC2A1 and cancer.